VEA Impex (I) Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: VEA Impex (I) Private Limited Pharmaceutical Export Portfolio Dataset — 14 Products, $229.9K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

VEA Impex (I) Private Limited — Pharmaceutical Exporter Profile (2026) | 14 Products, $229.9K Trade | TransData Nexus

VEA Impex (I) Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $229.9K Total Trade · DGFT Verified

VEA Impex (I) Private Limited is an Indian pharmaceutical exporter with a total trade value of $229.9K across 14 products in 3 therapeutic categories. Based on 348 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Darunavir ($59.4K), Daratumumab ($57.9K), Nivolumab ($27.9K).

VEA Impex (I) Private Limited — Export Portfolio & Destination Treemap

VEA Impex (I) Private Limited pharmaceutical export portfolio — 14 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is VEA Impex (I) Private Limited? — Company Overview & Market Position

Vea Impex (I) Private Limited is an Indian pharmaceutical exporter established on June 17, 2019, in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U51909MH2019PTC326863. It operates as a private limited company with an authorized and paid-up capital of ₹500,000. The registered office is located at Unit No.6 1-C, Ground Floor, Hitex Embroidery Estate Vardhman Compound, S.V. Road, Dahisar East, Mumbai, Maharashtra, 400068, India. The company is unlisted and has been active since its incorporation.

Vea Impex (I) Private Limited specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans 14 products across three therapeutic categories: Advanced Oncology (60.0%), Antiviral & HIV Medications (25.9%), and Brand Names & OTC Products (14.1%). The top five products by export value are Darunavir ($59K), Daratumumab ($58K), Nivolumab ($28K), Cetuximab ($22K), and Vinorelbine ($13K), collectively accounting for 78.5% of the total export value.

What Does VEA Impex (I) Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Darunavir$59.4K

Product Portfolio — Top 14 by Export Value

VEA Impex (I) Private Limited exports 14 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Darunavir	Antiviral & HIV Medications	$59.4K	4	0.1%	9
2	Daratumumab	Advanced Oncology	$57.9K	9	4.3%	6
3	Nivolumab	Advanced Oncology	$27.9K	4	1.2%	7
4	Cetuximab	Advanced Oncology	$22.5K	7	1.6%	7
5	Vinorelbine	Advanced Oncology	$12.6K	7	0.4%	10
6	Brufen	Brand Names & OTC Products	$9.3K	86	0.2%	10
7	Olaparib	Advanced Oncology	$8.6K	4	0.9%	11
8	Volini	Brand Names & OTC Products	$8.5K	48	0.3%	7
9	Neosporin	Brand Names & OTC Products	$8.3K	74	6.4%	5
10	Lomustine	Advanced Oncology	$4.3K	34	4.2%	6
11	Regorafenib	Advanced Oncology	$4.0K	4	0.4%	11
12	Crocin	Brand Names & OTC Products	$3.0K	23	3.5%	3
13	Combiflam	Brand Names & OTC Products	$2.2K	30	9.1%	2
14	Soframycin	Brand Names & OTC Products	$1.2K	14	0.2%	4

VEA Impex (I) Private Limited exports 14 pharmaceutical products across 3 therapeutic categories with a total export value of $229.9K. The top category is Advanced Oncology (60.0% of portfolio), followed by Antiviral & HIV Medications (25.9%), indicating a concentrated portfolio with the top 5 products accounting for 78.5% of total export value.

VEA Impex (I) Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vea Impex (I) Private Limited operates as a trading and distribution entity, sourcing pharmaceutical products from various manufacturers. The company does not own manufacturing facilities but partners with reputable drug manufacturing brands to procure medicines. These partners adhere to Good Manufacturing Practice (GMP) and World Health Organization (WHO) norms, ensuring the quality and efficacy of the products.

3Key Leadership

The leadership team of Vea Impex (I) Private Limited comprises:

Manthan Shah Rohit: Director
Manan Harish Shah: Director
Yash Hemantbhai Shah: Director
Sandeep Ghatalia Harshad: Director
Ruchi Manthan Shah: Director (appointed on September 30, 2025)

These directors collectively oversee the strategic direction and operations of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does VEA Impex (I) Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vea Impex (I) Private Limited exports pharmaceutical products to several regulated markets, including the United States, European Union, United Kingdom, Australia, and New Zealand. The company ensures compliance with the regulatory requirements of these markets, facilitating market access and distribution. Specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed.

2Emerging Markets

The company has a presence in emerging markets such as Africa, Latin America, and Southeast Asia. By partnering with credible entities capable of large-scale production in accordance with stringent GMP and WHO norms, Vea Impex (I) Private Limited aims to expand its reach in these regions.

3Geographic Strategy

Vea Impex (I) Private Limited demonstrates a diversified geographic strategy by exporting to both regulated and emerging markets. This approach mitigates concentration risk and positions the company to leverage growth opportunities across different regions. The strategic direction focuses on expanding market presence while maintaining compliance with international standards.

VEA Impex (I) Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Vea Impex (I) Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company ensures compliance with relevant regulatory standards to facilitate market access in the United States.

2WHO & EU GMP

Vea Impex (I) Private Limited partners with manufacturers that adhere to WHO and EU Good Manufacturing Practice (GMP) standards. This collaboration ensures that the pharmaceutical products meet international quality standards, enhancing the company's credibility in global markets.

3CDSCO & Indian Regulatory

The company operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. Vea Impex (I) Private Limited ensures compliance with Indian regulatory requirements to maintain its operational status.

VEA Impex (I) Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vea Impex (I) Private Limited operates in a competitive pharmaceutical export market, facing competition from both established and emerging companies. While specific competitors are not identified, the company's focus on quality, compliance, and strategic partnerships positions it to effectively compete in the global market.

2Key Differentiators

Vea Impex (I) Private Limited's key differentiators include its commitment to quality, adherence to international manufacturing standards, and strategic partnerships with leading drug manufacturing brands. These factors contribute to the company's ability to offer a diverse product portfolio and maintain a strong presence in the pharmaceutical export market.

3Strategic Position

The company's strategic direction focuses on expanding its presence in both regulated and emerging markets. By partnering with credible manufacturers and ensuring compliance with international standards, Vea Impex (I) Private Limited aims to strengthen its position in the global pharmaceutical export sector.

Buyer Due Diligence Brief — Evaluating VEA Impex (I) Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vea Impex (I) Private Limited demonstrates a strong track record in sourcing pharmaceutical products from reputable manufacturers. The company's export volume and consistency reflect its reliability in the market. By partnering with manufacturers that adhere to stringent GMP and WHO norms, Vea Impex (I) Private Limited ensures the quality and efficacy of its product offerings.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practice standards.

EU GMP Certification: Verify that the products meet European Union Good Manufacturing Practice standards.

Frequently Asked Questions — VEA Impex (I) Private Limited

How many pharmaceutical products does VEA Impex (I) Private Limited export from India?

VEA Impex (I) Private Limited exports 14 pharmaceutical products across 3 therapeutic categories. The top exports are Darunavir ($59.4K), Daratumumab ($57.9K), Nivolumab ($27.9K), Cetuximab ($22.5K), Vinorelbine ($12.6K). Total export value is $229.9K.

What is VEA Impex (I) Private Limited's total pharmaceutical export value?

VEA Impex (I) Private Limited's total pharmaceutical export value is $229.9K, based on 348 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does VEA Impex (I) Private Limited cover?

VEA Impex (I) Private Limited exports across 3 therapeutic categories. The largest are Advanced Oncology (60.0%, 7 products), Antiviral & HIV Medications (25.9%, 1 products), Brand Names & OTC Products (14.1%, 6 products).

Get Full VEA Impex (I) Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.